☆ 4.6 Article

Observational study of medical marijuana as a treatment for treatment-resistant epilepsies

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex A Placebo-Controlled Randomized Clinical Trial

Elizabeth A. Thiele et al.

Summary: Cannabidiol significantly reduced TSC-associated seizures compared with placebo, with the 25-mg/kg/day dosage having a better safety profile. Both dosages were equally efficacious in reducing seizures, but the smaller dosage led to fewer adverse events.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Antiseizure effects of the cannabinoids in the amygdala-kindling model

Merrick S. Fallah et al.

Summary: Objective Focal impaired awareness seizures (FIASs) are the most common seizure type in adults and are often refractory to medication. Management of FIASs is clinically challenging, and new interventions are needed for better seizure control. The amygdala-kindling model is a preclinical model of FIASs with secondary generalization. The present study assessed the efficacy of cannabidiol (CBD), increment 9-tetrahydrocannabinol (THC), and a combination of CBD and THC in a 15:1 ratio at suppressing focal and secondarily generalized seizures in the amygdala-kindled rat.

EPILEPSIA (2021)

添加到收藏夹

Article Medicine, General & Internal